Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Berdel AF, Schwöppe C, Brand C, Harrach S, Brömmel K, Hintelmann H, Lenz G, Liersch R, Heinzow H, Schliemann C, Mesters RM, Berdel WE, Kessler T. Berdel AF, et al. Cancers (Basel). 2021 Jun 7;13(11):2841. doi: 10.3390/cancers13112841. Cancers (Basel). 2021. PMID: 34200318 Free PMC article. Review.
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C. Berdel AF, et al. Blood Adv. 2022 Jun 28;6(12):3684-3696. doi: 10.1182/bloodadvances.2021006909. Blood Adv. 2022. PMID: 35468621 Free PMC article. Clinical Trial.
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
Schliemann C, Kessler T, Berdel AF, Hemmerle T, Angenendt L, Altvater B, Rossig C, Mikesch JH, Lenz G, Schäfers M, Neri D, Stelljes M, Berdel WE. Schliemann C, et al. Among authors: berdel af. Br J Haematol. 2021 Mar;192(6):e148-e151. doi: 10.1111/bjh.17365. Epub 2021 Feb 22. Br J Haematol. 2021. PMID: 33618424 Clinical Trial. No abstract available.
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Berdel AF, Koch R, Gerss J, Hentrich M, Peceny R, Bartscht T, Steffen B, Bischoff M, Spiekermann K, Angenendt L, Mikesch JH, Kewitz T, Butterfass-Bahloul T, Serve H, Lenz G, Berdel WE, Krug U, Schliemann C. Berdel AF, et al. Ann Hematol. 2023 Jan;102(1):63-72. doi: 10.1007/s00277-022-05025-0. Epub 2022 Nov 18. Ann Hematol. 2023. PMID: 36399194 Free PMC article. Clinical Trial.
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
Schliemann C, Hemmerle T, Berdel AF, Angenendt L, Kerkhoff A, Hering JP, Heindel W, Hartmann W, Wardelmann E, Chawla SP, de Braud F, Lenz G, Neri D, Kessler T, Berdel WE. Schliemann C, et al. Among authors: berdel af. Eur J Cancer. 2021 Jun;150:143-154. doi: 10.1016/j.ejca.2021.03.038. Epub 2021 Apr 23. Eur J Cancer. 2021. PMID: 33901793 Clinical Trial.
Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease.
Gerwing M, Krähling T, Schliemann C, Harrach S, Schwöppe C, Berdel AF, Klein S, Hartmann W, Wardelmann E, Heindel WL, Lenz G, Berdel WE, Wildgruber M. Gerwing M, et al. Among authors: berdel af. Cancers (Basel). 2021 Nov 23;13(23):5880. doi: 10.3390/cancers13235880. Cancers (Basel). 2021. PMID: 34884988 Free PMC article.
Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
Berdel WE, Harrach S, Brand C, Brömmel K, Berdel AF, Hintelmann H, Schliemann C, Schwöppe C. Berdel WE, et al. Among authors: berdel af. Cancers (Basel). 2020 Nov 26;12(12):3536. doi: 10.3390/cancers12123536. Cancers (Basel). 2020. PMID: 33256235 Free PMC article.
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE. Schliemann C, et al. Among authors: berdel af. Cancers (Basel). 2020 Jun 7;12(6):1488. doi: 10.3390/cancers12061488. Cancers (Basel). 2020. PMID: 32517329 Free PMC article.